The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
M Grymonprez, M Petrovic… - Thrombosis and …, 2024 - thieme-connect.com
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation
G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation
DJ Graham, E Baro, R Zhang, J Liao… - The American Journal of …, 2019 - Elsevier
Background Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease
I Moon, SR Lee, EK Choi, E Lee, JH Jung… - Journal of Clinical …, 2019 - mdpi.com
Background: There are limited data for non-vitamin K antagonist oral anticoagulants
(NOACs) impact on outcomes for patients with atrial fibrillation (AF) and valvular heart …
(NOACs) impact on outcomes for patients with atrial fibrillation (AF) and valvular heart …
[HTML][HTML] Low-dose NOACs versus standard-dose NOACs or warfarin on efficacy and safety in Asian patients with NVAF: a meta-analysis
Z Li, Y Zheng, D Li, X Wang, S Cheng… - Anatolian Journal of …, 2022 - ncbi.nlm.nih.gov
Background: The meta-analysis of randomized controlled trials has illustrated that the
efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with …
efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with …
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
M Grymonprez, TL De Backer, A Capiau… - British Journal of …, 2023 - Wiley Online Library
Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
[HTML][HTML] Off-label underdosing or overdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis
X Wu, L Hu, J Liu, Q Gu - Frontiers in Cardiovascular Medicine, 2021 - frontiersin.org
Background: Several studies have investigated the role of off-label non-vitamin K antagonist
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …
CO156 Direct Oral Anticoagulants in Adults with Non-Valvular Atrial Fibrillation: Systematic Review and Network Meta-Analysis of Real-World Evidence
R Subash, S Lister, C Lewis, S Rabar… - Value in …, 2023 - valueinhealthjournal.com
Objectives Vitamin K antagonists (VKAs) such as warfarin, and direct oral anticoagulants
(DOACs) such as apixaban, dabigatran, edoxaban, and rivaroxaban are routinely …
(DOACs) such as apixaban, dabigatran, edoxaban, and rivaroxaban are routinely …
The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
M Grymonprez, TL De Backer, X Bertels, S Steurbaut… - Europace, 2023 - academic.oup.com
Abstract Funding Acknowledgements Type of funding sources: Public grant (s)–National
budget only. Main funding source (s): Research Foundation Flanders (Fonds …
budget only. Main funding source (s): Research Foundation Flanders (Fonds …